Systemic Chemotherapy for Advanced or Recurrent Endometrial Cancer

  • Hans-Gerd Meerpohl
Part of the AGO Arbeitsgemeinschaft für Gynäkologische Onkologie book series (AGO)


For several reasons it is most common to regard endometrial cancer as a curable disease. Clinical symptoms occur early in the disease course and for the majority of patients the disease is at the time of diagnosis confined to the corpus of the uterus (FIGO-stage I). Such lesions are almost always well differentiated and a complete cure resulting from the standard treatment of surgery ± radiotherapy occurs in about 90% of the patients [1]. Despite this evidence of success one have to take in consideration also the backside of the coin. It shows, that about one-third of all patients with this malignancy recur within 5 years from the time of diagnosis. For the Federal Republic of Germany for example this situation means that approximately 2800 patients present annually with locally advanced or recurrent disease [2] (Table 1). This group of patients but doesn’t suffer from a harmless disease but are possible candidates for more effective treatment approaches.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    FIGO (1985): Annual report on gynecological cancer. International Federation of Gynecology and Obstetrics. Vol. 19Google Scholar
  2. 2.
    Mailänder J. (1987): Morbidität und Mortalität an bösartigen Neubildungen im Saarland 1986. Jahresbericht des Saarländischen Krebsregisters. In: Saarland in Zahlen (Sonderheft)Google Scholar
  3. 3.
    Donovan JF (1974): Nonhormonal chemotherapy of advanced endometrial adenocarcinoma: a review Cancer 34: 1587–1592PubMedCrossRefGoogle Scholar
  4. 4.
    DeVita VT, Wasserman T, Young RC et al.(1976): Perspectives and research in gynecologic oncology. Cancer 38: 509–525CrossRefGoogle Scholar
  5. 5.
    Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA (1979): Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial adenocarcinoma: A Gynecological Oncology Group Study Cancer Treat. Rep. 63: 21–27PubMedGoogle Scholar
  6. 6.
    Horton J, Begg CB, Arseneault J, Bruckner H. et al (1978): Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat. Rep. 62: 159–161PubMedGoogle Scholar
  7. 7.
    Trope C, Grundseil H, Johnson J. et al. (1980): A phase II study of cisplatinum for recurrent corpus cancer. Eur. J. Cancer 16: 1025–1026PubMedCrossRefGoogle Scholar
  8. 8.
    Seski J, Edwards C, Herson J. et al (1982): Cisplatin chemotherapy for disseminated endometrial cancer. Obstet. Gynecol. 7: 253–256Google Scholar
  9. 9.
    Thigpen T, Blessing J, Lagasse C, DiSaia P, Homesley H. (1984): Phase II trial of cisplatin as second line chemotherapy in patients with advanced or recurrent endometrial carcinoma. Amer. J. Clin. Oncol. 7: 253–256CrossRefGoogle Scholar
  10. 10.
    Deppe G, Cohen C, Bruckner HW. (1980): Treatment of advanced endometrial adenocarcinoma with cisdichlorodiammineplatinum II after intensive prior therapy. Gynecol. Oncol. 10: 51–54PubMedCrossRefGoogle Scholar
  11. 11.
    Thigpen JT (1980): Cisplatin in the treatment of advanced cervix and uterus cancer. Current status and new developments. Pestoyko AW, Crooke ST, Carter SK (eds) Academic Press NY pp: 411–421Google Scholar
  12. 12.
    Long HJ, Pfeif le DM, Wieand HS, Krook JE et al.(1988): Phase II evaluation of carboplatin in advanced endometrial carcinoma. J.Natl. Cancer Instit. 80: 276–278CrossRefGoogle Scholar
  13. 13.
    Green JB, Green ST, Alberts DS, O’Toole R, Surwit EA, Noltimier JW (1990): Carboplatin therapy in advanced endometrial cancer. Obstet. Gynecol. 75: 696–700PubMedGoogle Scholar
  14. 14.
    Thigpen J. (1989): Systemic therapy with single agents for advanced or recurrent endometrial carcinoma. In: Surwit EA, Alberts DS (eds) Endometrial Cancer In: Cancer treatment and research (Series ed.: McGuire WL) Kluwer Academic Publishers Boston 1989 pp: 93–106Google Scholar
  15. 15.
    Johnson RK, Zee-Cheng RKY, Lee WW et al. (1979): Experimental antitumor activity of aminoanthraquinone Cancer Treat. Rep. 63: 425–439PubMedGoogle Scholar
  16. 16.
    von Hoff DD, Coltman DSjr, Forseth B. (1981): Activity of mitoxantrone in a human tumor cloning system. Cancer Res. 41: 1853–1855Google Scholar
  17. 17.
    Runge M., Meerpohl HG, Pfleiderer, A. (1989): Mitoxantrone therapy of advanced adenocarcinoma of the endometrium. Onkologie 12: 102–103PubMedCrossRefGoogle Scholar
  18. 18.
    Brunner KW. (1987): Effects and side effects of chemotherapy in endometrial cancer. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds.) Endometrial cancer Zuckschwerdt Verlag München 1987 pp: 181–189Google Scholar
  19. 19.
    Thigpen JT, Blessing J, DiSaia P. (1985): A randomized comparison of adriamycin with or without cyclophosphamide in the treatment of advanced or recurrent endometrial cancer. Proc. Am. Soc. Clin. Oncol. 4: 115Google Scholar
  20. 20.
    Seltzer V, Vogl SE, Kaplan BH. (1984): Adriamycin and cis-diamminedi- chloroplatinum in the treatment of metastatic endometrial adenocarcinoma. Gynecol. Oncol. 19: 308–313PubMedCrossRefGoogle Scholar
  21. 21.
    Trope C, Johnson JE, Simonsen E, Christiansen H. et al.(1984): Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatinum. Am.J. Obstet. Gynecol. 149: 1025–1026Google Scholar
  22. 22.
    Malviya VK, Deppe G. (1987): Treatment of advanced recurrent endometrial cancer with cisplatin in combination chemotherapy. Poster presentation to the Society of Gynecol. Oncologists (SGO) Miami, Florida, February 3, 1987Google Scholar
  23. 23.
    Edmonson JH, Krook JE, Hilton JF, Malkasian JD et al. (1987): Randomized phase II studies of cisplatinand a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin- refractory advanced endometrial carcinoma. Gynecol.Oncol. 28: 20–24PubMedCrossRefGoogle Scholar
  24. 24.
    Cohen CJ, Bruckner HW, Deppe G. et al.(1980): A randomized study comparing multidrug chemotherapy regimens in the treatment of advanced and recurrent endometrialcarcinoma: A Gynecologic Oncology Group Study. Obstet. Gynecol 63: 719–725Google Scholar
  25. 25.
    Horton J, Elson P, Gordon P, Hahn R, Creech R. (1982): Combination chemotherapy of advanced endometrial cancer. An evaluation of three regimens. Cancer 49: 2441–2445PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Hans-Gerd Meerpohl

There are no affiliations available

Personalised recommendations